PROCEPT BioRobotics Schedules Q2 2026 Earnings Call Amid BPH Treatment Expansion
Event summary
- PROCEPT BioRobotics will report Q2 2026 financial results on August 4, 2026.
- Conference call scheduled for 4:30 p.m. Eastern Time following the earnings release.
- Company focuses on urology solutions with AQUABEAM® and HYDROS® Robotic Systems.
- HYDROS is the only AI-powered robotic technology delivering Aquablation therapy.
- PROCEPT has published approximately 250 peer-reviewed studies supporting its therapies.
The big picture
PROCEPT BioRobotics is positioning itself as a leader in urology-focused robotic surgery, leveraging AI to deliver Aquablation therapy. The company's focus on BPH treatment comes at a time when demand for minimally invasive solutions is rising, particularly among an aging male population. With approximately 40 million men in the U.S. affected by BPH, PROCEPT’s ability to scale its technology will be critical in maintaining market share against competitors.
What we're watching
- Revenue Growth
- Whether PROCEPT can sustain its expansion in BPH treatment market.
- Clinical Adoption
- The pace at which peer-reviewed evidence translates into broader clinical adoption.
- Competitive Positioning
- How PROCEPT differentiates itself in the growing AI-powered surgical robotics space.
Related topics